The
fatty acid-based microparticles containing iron oxide nanoparticles
and paclitaxel (PAX) are a viable proposition for the treatment of
lung cancer. The microparticles inhaled as a dry powder can be guided
to selected locations using an external magnetic field, and when accumulated
there, the active compound release can be triggered by local hyperthermia.
However, this general strategy requires that the active compound is
released from microparticles and can reach the targeted cells before
microparticles are removed. Isothermal titration calorimetry was used
to demonstrate that the components of microparticles were released
and transferred to albumins and lipid bilayers. The morphology of
the measured particulates was studied with scanning electron microscopy
and dynamic light scattering. To determine the cytotoxicity of microparticles,
cell culture studies were done. It has been shown that the transfer
efficiency depends predominantly on the fatty acid composition of
microparticles, which, together with the active ingredient, accumulate
predominantly in membrane structures after being released from microparticles
and before entering the cytoplasm. The release process is sufficient;
hence, paclitaxel-loaded microparticles effectively suppressed the
proliferation of A549 human lung epithelial cells of malignant origin
(IC
50
values for both lauric acid-based and myristic/palmitic-based
microparticles containing paclitaxel were below 0.375 μg/mL),
while reference microparticles were noncytotoxic.